Pharvaris N.V. (NASDAQ:PHVS) Given Consensus Recommendation of "Moderate Buy" by Analysts

Key Points

• Analysts give Pharvaris a “Moderate Buy” consensus: Eleven of 14 analysts rate the stock a buy, one rates it a strong buy, while one each issue hold and sell ratings. The average 12-month price target is $51.08 versus a recent price of $35.66.
• Pharvaris reported a quarterly EPS miss, posting a loss of $0.81 per share versus the $0.75 loss expected by analysts. The clinical-stage biotechnology company is developing oral therapies for hereditary angioedema, including its lead candidate PHA121.
• Institutional investors increased their exposure, including new investments by venBio Partners and larger holdings from Deerfield Management, Wellington Management and Paradigm Biocapital. However, insiders sold 118,655 shares worth approximately $4.19 million over the last quarter.

Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) has earned a consensus rating of "Moderate Buy" from the fourteen brokerages that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $51.0769.

A number of equities analysts have recently weighed in on PHVS shares. Wall Street Zen lowered Pharvaris from a "hold" rating to a "sell" rating in a research note on Saturday, July 18th. Citigroup reissued a "market outperform" rating on shares of Pharvaris in a research note on Thursday, August 13th. Morgan Stanley boosted their price target on Pharvaris from $41.00 to $46.00 and gave the stock an "overweight" rating in a report on Thursday, June 25th. Guggenheim upped their price target on Pharvaris from $39.00 to $40.00 and gave the stock a "buy" rating in a research note on Thursday, August 13th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Pharvaris in a report on Friday, July 17th.

Pharvaris Stock Performance

PHVS opened at $35.66 on Friday. The stock has a market cap of $2.33 billion, a price-to-earnings ratio of -11.69 and a beta of -2.33. The firm's fifty day moving average is $34.76 and its 200 day moving average is $31.00. Pharvaris has a fifty-two week low of $20.65 and a fifty-two week high of $38.13.

Pharvaris (NASDAQ:PHVS - Get Free Report) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). On average, equities research analysts predict that Pharvaris will post -3.15 earnings per share for the current year.

Insider Transactions at Pharvaris

In related news, Director Johannes Gerardus Chri Schikan sold 30,712 shares of the company's stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $35.49, for a total transaction of $1,089,968.88. Following the completion of the transaction, the director owned 315,167 shares in the company, valued at approximately $11,185,276.83. This represents a 8.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Berndt Modig sold 2,292 shares of the firm's stock in a transaction on Friday, August 14th. The shares were sold at an average price of $34.77, for a total transaction of $79,692.84. Following the transaction, the chief executive officer directly owned 130,625 shares of the company's stock, valued at $4,541,831.25. The trade was a 1.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 118,655 shares of company stock valued at $4,188,002. 11.84% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. venBio Partners LLC purchased a new stake in shares of Pharvaris in the second quarter worth about $160,569,809. Deerfield Management Company L.P. grew its holdings in Pharvaris by 21.1% during the 3rd quarter. Deerfield Management Company L.P. now owns 2,442,464 shares of the company's stock valued at $60,939,000 after buying an additional 425,000 shares in the last quarter. Wellington Management Group LLP increased its stake in Pharvaris by 12.9% in the 2nd quarter. Wellington Management Group LLP now owns 2,392,934 shares of the company's stock worth $82,748,000 after acquiring an additional 274,034 shares during the last quarter. Commodore Capital LP raised its holdings in shares of Pharvaris by 1.6% during the 1st quarter. Commodore Capital LP now owns 1,918,970 shares of the company's stock worth $54,211,000 after acquiring an additional 29,525 shares in the last quarter. Finally, Paradigm Biocapital Advisors LP raised its holdings in shares of Pharvaris by 72.7% during the 3rd quarter. Paradigm Biocapital Advisors LP now owns 1,835,494 shares of the company's stock worth $45,796,000 after acquiring an additional 772,583 shares in the last quarter.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company's core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company's lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source